Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer

Fig. 2

a IC50 for CDDP treated KY-SE150 and Eca-9706. b IC50 for CPB treated KY-SE150 and Eca-9706. c IC50 for L-OHP treated KY-SE150 and Eca-9706. df m6A level for CDDP, CPB and L-OHP treated LY-SE150 and Eca-9706. gi SNHG3, METTL3 and miR-186-5p level for CDDP treated LY-SE150 and Eca-9706. jl SNHG3, METTL3 and miR-186-5p level for CPB treated LY-SE150 and Eca-9706. mo SNHG3, METTL3 and miR-186-5p level for L-OHP treated LY-SE150 and Eca-9706

Back to article page